Travere Therapeutics, Inc.
TVTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.1B
$65.28
▼ -1.89%
P/E
-85.89
Mkt Cap
$6.1B
52-Wk Range
$20.84–$68.03
52-Week Range
$20.84 - $68.03
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 207.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Established portfolio of FDA-approved rare disease medications with limited competition
- Specialized expertise in rare metabolic and genetic disorder treatment
- Strategic partnerships with NIH and patient advocacy organizations for drug discovery
- Orphan drug designations providing regulatory and market exclusivity benefits
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Sparsentan Phase III clinical trial advancement for FSGS and IgA nephropathy treatment
Value
Valuation data unavailable
Momentum
Hot
+38.7% over 3m
Quality
Excellent
High-growth business (77% revenue growth, 94% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying TVTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 4, 2026
Reported EPS of -$0.37 vs -$0.13 consensus (-174.8% surprise). Revenue of $169.6M vs $157.3M expected (+7.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-174.8%
Revenue trend · last 8Q
—
+66%
+98%
+111%
+162%
+73%
+56%
+48%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$62.9M
$74.8M
$81.7M
$114.4M
$164.9M
$129.7M
$127.2M
$169.6M
Margins · last 8Q
Gross
0.0%
Operating
2.3%
Profit
-20.5%
Wall Street consensus
10 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 17, 2026
vs Industry
How TVTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related